Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.
Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R, Klümpen HJ, Cremer B, Sevilla I, Eriksson B, Tabaksblat E, Metges JP, Reed NS, Schrader J, Navarro V, Valentí V, Hernando J, Colao AM, Vestermark L, Carnaghi C, Knigge UP, Jimenez-Fonseca P, Benavent M, de Vos-Geelen J, Venerito M, Von Werder A, Jann H, Rinke A, Smith D, Hörsch D, Starling N, Ruszniewski P, Baudin E, Caroli-Bosc FX, Manzano JL, Martín M, Scarpa A, Lawlor RT, Ragulan C, Ps H, Sadanandam A, Carmona-Bayonas A, Salazar R.
Capdevila J, et al. Among authors: horsch d.
ESMO Open. 2025 Dec;10(12):105922. doi: 10.1016/j.esmoop.2025.105922. Epub 2025 Dec 2.
ESMO Open. 2025.
PMID: 41337860
Free PMC article.
Clinical Trial.